Recent News for GBT - Global Blood Therapeutics, Inc.

Date Title
Aug 9 50 Healthcare Stocks Moving In Thursday's After-Market Session
Aug 7 Global Blood Therapeutics EPS misses by $0.06
Aug 7 GBT Reports Recent Business Progress and Second Quarter 2019 Financial Results
Aug 6 GBT Announces Participation at the 2019 Wedbush PacGrow Healthcare Conference
Aug 3 29 Healthcare Stocks Moving In Friday's After-Market Session
Jul 30 Revisiting Global Blood Therapeutics
Jul 29 Global Blood Therapeutics: A Promising Biotech Pick In 2019
Jul 29 The Totality Of Voxelotor Phase 3 Data Increases My Conviction In Global Blood Therapeutics
Jul 25 5 Biotech Stocks to Buy for Blockbuster Potential
Jul 16 Should You Pick Up Novartis (NVS) Before Q2 Earnings?
Jul 16 Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA
Jul 10 GBT and Advocates Launch Disease Awareness Campaign Focused on Breaking Down Stigmas Associated with Sickle Cell Disease
Jul 9 Global Blood Therapeutics: My 3 Reasons For A Buy
Jul 6 Global Blood Therapeutics: Raining In The Desert With Voxelotor
Jul 5 Local researcher part of 'exciting' sickle cell drug trial
Jul 3 Global Blood Therapeutics: Voxelotor Can Take The Stock Price To New All-Time Highs
Jun 26 Why BlackBerry, AeroVironment, and Global Blood Therapeutics Slumped on Wednesday
Jun 26 INO, XSPA, EROS and GBT among midday movers
Jun 26 Inovio Pharmaceuticals and Neos Therapeutics among healthcare gainers; Mesoblast and OncoCyte among losers
Jun 26 Global Blood prices $200M stock offering, shares down 6% premarket
Jun 26 GIS and LILAK among premarket losers
Jun 26 Global Blood Therapeutics Prices a $200.0 Million Common Stock Public Offering
Jun 26 The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart
Jun 25 Global Blood down 4% after hours on $200M equity offering
Jun 25 Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
Back to the Main GBT Page...